![]() ![]() “Current treatments focus on symptoms but do not address the underlying causes of neurodegeneration. ![]() We believe MRx0005 and MRx0029 are the first-ever Live Biotherapeutic products for Parkinson’s to enter the clinic,” The first study in-human will test the safety of the drugs, including their effectiveness against the disease biomarkers, after which the company can move to phase 2 clinical trials.ĭr Alex Stevenson, 4D Pharma’s Chief Scientific Officer, said: “Entering the clinic with our novel CNS programs stemming from our proprietary MicroRx platform will represent an important step for 4D Pharma’s continued growth and leadership in the microbiome field. In addition, the drugs have been tested in animal models and protected against the loss of dopamine metabolites and dopamine-producing neurons in the brain. The two drugs have shown effectiveness against gut barrier integrity, oxidative stress, neuroinflammation and neuroprotection. Also, Read The Best Biotech Penny Stocks Under $5 To Buy Right Now.Ĥd Pharma clarified that MRx0005 and MRx0029 are two separate single strain Live Biotherapeutic candidates that have demonstrated effectiveness against various aspects of Parkinson’s disease in pre-clinical trials. The company expects to start in-human trials in mid-2022. The two drugs are, MRx0005 and MRx0029, which have different treatment mechanisms, will be investigated to measure their effectiveness against Parkinson’s.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |